A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
← catalyst calendarNCT06615050 · readout in 1,612 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →. With Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI).
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
572estimated
Sites
30
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-02 | actual | When the study began enrolling |
| Primary completion | 2031-01-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-17 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Graft-versus-host Disease (GVHD)
Interventions
- Drug: Tacrolimus (Tac)
- Drug: Methotrexate (MTX)
- Drug: Ruxolitinib (Rux) — also filed as Jakafi, INCB018424
- Drug: Cyclophosphamide
- Drug: Mycophenolate mofetil (MMF)
Primary outcome
what the primary-completion date above is the date OFGVHD-free survival (GFS)
measured Up to 24 months post-transplant (Day 0)
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed